-
-
-
-
-
-
-
PFE builds bull case at $26 after earnings beat and insider buys
-
-
-
-
-
-
-
FDA grants priority review for Pfizer's Talzenna and Xtandi combo in prostate cancer
-
-
-
-
-
-
-
FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance
-
-
-
-
-
-
-
Pfizer CFO Dave Denton to leave for consumer goods role
-
-
-
-
-
-
-
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
-
-
-
-
-
-
-
Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
-
-
-
-
-
-
-
Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
-
1,225,979 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

